EAM Investors’s iTeos Therapeutics ITOS Stock Holding History

EAM Investors’s Portfolio ITOS Stock Details ITOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-65,707	Closed	-$3.06M	–	331
2021 Q4	$3.06M	Buy	+65,707	New	+$2.19M	0.5%	52

Other funds holding ITOS

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

EAM Investors's ITOS Position: Q1 2022 in Review

EAM Investors sold out of iTeos Therapeutics (ITOS) in Q1 2022, closing a stake of 65,707 shares — an estimated $3.06M sold.

EAM Investors first reported a position in ITOS in Q4 2021 and held it in 1 quarter. The position peaked at $3.06M in Q4 2021. 159 funds tracked by Wall St. Rank hold ITOS as of Q1 2022.

EAM Investors reported no remaining iTeos Therapeutics position as of Q1 2022 after selling out during the quarter.
EAM Investors sold 65,707 iTeos Therapeutics shares in Q1 2022, an estimated $3.06M.
EAM Investors first reported a position in iTeos Therapeutics in Q4 2021 and held it in 1 quarter.
EAM Investors's iTeos Therapeutics position peaked at $3.06M in Q4 2021.
159 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q1 2022.

Based on EAM Investors's 13F filing for Q1 2022, filed 13 May 2022.